| I----- ational Application No

A. CLASSII IPC 7	FICATION OF SUBJECT MATTER A61K35/78 A61P29/00		
According to	International Patent Classification (IPC) or to both national classifica	otion and IPC	
B. FIELDS		and if C	
Minimum do IPC 7	cumentation searched (classification system followed by classification $A61K$ $A61P$	on symbols)	
Documentat	ion searched other than minimum documentation to the extent that so	uch documents are included in the fields se	arched
Electronic da	ata base consulted during the international search (name of data bas	se and, where practical, search terms used	
EPO-In	ternal, WPI Data, PAJ, BIOSIS, EMBAS	SE, FSTA	
С. РОСИМ	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with Indication, where appropriate, of the rele	evant passages	Relevant to claim No.
Χ	CHRUBASIK S ET AL: "TREATMENT OF RHEUMATIC PAIN WITH HERBAL MEDICI EUROPE"	INE IN	1-6
•	PAIN DIGEST, SPRINGER, NEW YORK, vol. 8, no. 4, 1998, pages 231-23 XP009014438 ISSN: 0938-9016 page 231, column 1, paragraphs 2,	36,	
X	table 2 DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (BETHESDA, MD, US; 2002.	(NLM),	1–6
	CHRUBASIK SIGRUN ET AL: "'Pain ma with herbal antirheumatic drugs!" XP002298411 Database accession no. NLM1201774 abstract abstract		
		-/	
	ner documents are listed in the continuation of box C.	Patent family members are listed	n annex.
"A" docume considure earlier of filing of L" docume which citatio "O" docume other other "P" docume	ent defining the general state of the art which is not lered to be of particular relevance document but published on or after the international late ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filling date but and the priority date claimed	 "T" later document published after the Interior priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an Inventive step when the document of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combination being obvious the art. 	the application but early underlying the slaimed invention to considered to current is taken alone slaimed invention ventive step when the ore other such docuus to a person skilled
	actual completion of the International search	*&" document member of the same patent Date of mailing of the international sea	
	9 September 2004	20/10/2004	ιωι ισμυιι
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Authorized officer Peris Antoli, B	

ational Application No

		PC 1/EP2004/0058/5
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	& WIENER MEDIZINISCHE WOCHENSCHRIFT (1946) 2002, vol. 152, no. 7-8, 2002, pages 198-203, ISSN: 0043-5341	
X	US 5 629 351 A (TANEJA SUBHASH C ET AL) 13 May 1997 (1997-05-13) claim 2 column 4, lines 40-45	1-6
X	US 2002/010168 A1 (AMMON HERMANN P T ET AL) 24 January 2002 (2002-01-24) claims 1,2	1-6
X	DATABASE MEDLINE 'Online! US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 1999 (1999-09), ZHAO J ET AL: "Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3'-gallate as the most effective antioxidant constituent." XP002298412 Database accession no. NLM10469619 abstract: 1st sentence abstract & CARCINOGENESIS. SEP 1999, vol. 20, no. 9, September 1999 (1999-09), pages 1737-1745, ISSN: 0143-3334	1-6
X	US 4 870 061 A (SPECK ULRICH) 26 September 1989 (1989-09-26) claim 1	1-6
X	EP 0 864 580 A (HAYASHIBARA BIOCHEM LAB; CHUGOKU KAYAKU (JP)) 16 September 1998 (1998-09-16) page 4, lines 10-14	1–6
X	GB 1 015 800 A (FUJISAWA PHARMACEUTICAL CO) 5 January 1966 (1966-01-05) page 1, lines 28-31	1-6

International Application No
ITI/EP2004/005875

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document, with indication, where appropriate, of the relevant passages P, X TAMAI Y ET AL: "Enhanced healing of	Relevant to claim No.
	Relevant to claim No.
P.X TAMAT Y ET Al: "Enhanced healing of	
cartilaginous injuries by N-acetyl-d-glucosamine and glucuronic acid" CARBOHYDRATE POLYMERS, APPLIED SCIENCE PUBLISHERS, LTD. BARKING, GB, vol. 54, no. 2, 1 November 2003 (2003-11-01), pages 251-262, XP004452621 ISSN: 0144-8617 abstract page 262, column 1, paragraph 2	1-6

Information on patent family members

i----ational Application No

	ent document n search report		Publication date		Patent family member(s)	Pi	ublication date
US !	5629351	Α	13-05-1997	EP	0755940 A	1 29	9-01-1997
US 2	2002010168	A1	24-01-2002	DE	19531067 A	1 27	7-02-1997
				AT	200422 T	15	5-04-2001
				DE		1 17	7-05-2001
				DK		3 18	3-06-2001
				WO	9707796 A	.1 06	5-03-1997
				EP		1 29	9-07-1998
				ES		3 0:	1-08-2001
				JP	11511448 1		5-10-1999
				PT	854709 T	3(0-08-2001
US	4870061	Α	26-09-1989	DE	3602670 A	1 3	0-07-1987
				CA	1288346 (0:	3-09-1991
				EP	0234207 <i>F</i>	\2 0:	2-09-1987
				JP	62185017 <i>F</i>	1	3-08-1987
				ZA	8700074 A	2	5-05-1988
EP	0864580	Α	16-09-1998	JP	10251263 <i>I</i>	2	2-09-1998
				DE	69815179 i	1	0-07-2003
				DE	69815179	Γ2 1	9-05-2004
				EΡ	0864580	12 1	6-09-1998
	•			TW	476759 1	-	1-02-2002
				US	5912361	4 1	5-06-1999
GB	1015800	Α	05-01-1966	FR	3970		_ _

ternational application No.

INTERNATIONAL SEARCH REPORT

PCT/EP2004/005875

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The present invention relates to formulations comprising combinations of analgesic/anti-inflammatory, immunomodulating and cartilage-reconstructing agents, in particular comprising saligenin, boswellic acid, procyanidins, N-acetyl-glucosamine and either glucuronic acid or glucuronolactone, for the treatment of rheumatoid arthritis and, more generally, of arthritis conditions.						